Which company produces capmatinib?

Capmatinib (Capmatinib) is a targeted drug produced by Novartis and marketed under the brand name Tabrecta. The drug is mainly used to treat patients with non-small cell lung cancer (NSCLC) caused by MET exon 14 skipping mutations. Capmatinib is a small molecule kinase inhibitor that specifically targets c-Met (hepatocyte growth factor receptor, also known as HGFR), which plays an important role in the proliferation and migration of tumor cells. Novartis is a multinational pharmaceutical company headquartered in Switzerland, dedicated to the research, development and production of innovative drugs, covering multiple treatment areas, including tumors, cardiovascular, neurological diseases, etc.

c-Met is a receptor tyrosine kinase that participates in a variety of cellular functions in normal physiology, such as cell proliferation, migration, and angiogenesis. In some cases, abnormal activation of c-Met is closely related to the occurrence and development of tumors, so targeted drugs targeting c-Met have gradually become the focus of research and clinical application.

Capmatinib can effectively prevent the growth and spread of tumor cells by inhibiting thec-Met signaling pathway. This mechanism makes it an important treatment option for certain types of non-small cell lung cancer, especially in patients who do not respond well to conventional chemotherapy and immunotherapy. Novartis conducted extensive clinical trials during the development of capmatinib to evaluate its efficacy and safety. Studies have shown that capmatinib has a therapeutic effect on patients with non-small cell lung cancer carrying MET mutations or amplifications, and has improved tumor control rate and survival.

This achievement not only provides new treatment options for patients, but also adds more options for doctors to treat complex tumors. The drug was approved by the U.S. Food and Drug Administration (FDA) in 2020 and has been included in multiple treatment guidance plans, providing new treatment options for corresponding patients.